Chronic myeloid leukemia in the imatinib era

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


The results of imatinib (Gleevec) (formerly STI571) therapy for chronic myeloid leukemia (CML) have continued to improve and have surpassed almost everyone's predictions. However, the long-term results with imatinib and its ability to cure CML as a single agent are unknown. These issues will be discussed along with potential strategies to improve the cure rate, using imatinib as a building block to achieve this goal.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalSeminars in hematology
Issue number2 SUPPL. 2
StatePublished - Apr 2003

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Chronic myeloid leukemia in the imatinib era'. Together they form a unique fingerprint.

Cite this